diarrhea while on glp 1 tirzepatide (Mounjaro) affects approximately 23–31% of patients and is typically mild to moderate, transient, and most common during dose escalation. , It rarely requires discontinuation How GLP-1 changes the way
Pay in 4 interest-free payments of $6.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9












:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)













